Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
11.75
-0.11 (-0.93%)
Apr 25, 2025, 12:23 PM EDT - Market open
Mesoblast Employees
Mesoblast had 73 employees as of June 30, 2024. The number of employees decreased by 10 or -12.05% compared to the previous year.
Employees
73
Change (1Y)
-10
Growth (1Y)
-12.05%
Revenue / Employee
$77,671
Profits / Employee
-$1,415,767
Market Cap
1.46B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
MESO News
- 8 days ago - Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives - GlobeNewsWire
- 21 days ago - Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs - GlobeNewsWire
- 22 days ago - Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure - GlobeNewsWire
- 25 days ago - First Three Children to Commence Treatment With Ryoncil® - GlobeNewsWire
- 4 weeks ago - Ryoncil® is Now Available for Purchase in the United States - GlobeNewsWire
- 6 weeks ago - Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States - GlobeNewsWire
- 6 weeks ago - Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall - GlobeNewsWire
- 2 months ago - Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript - Seeking Alpha